Vidaza

For the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in patients not eligible for haematopoietic stem cell transplantation.

Azacitidine is an antineoplastic agent believed to exert its effects by multiple mechanisms, including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA.

The cytotoxic effects are thought to be as a result of DNA, RNA and protein synthesis inhibition as well as the activation of DNA damage pathways.

It is recommended that patients be treated for a minimum of six cycles and treatment should be continued as long as the patient continues to benefit or until disease progression. Each cycle consists of 28 days and patients should be monitored for haematologic response/toxicity and renal toxicities.

View Vidaza drug record

Further information: Celgene

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more